Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast

Not Applicable

Active, not recruiting

• Conditions: Low Risk DCIS; DCIS; Breast Cancer; Breast Conserving Surgery; Radiotherapy Omission
• Interventions: Other: No Radiotherapy; Radiation: Radiotherapy

• Registration Number: NCT03878342
• Lead Sponsor: UNICANCER

Brief Summary

Following breast-conserving surgery (BCS) for localized ductal carcinoma in situ (DCIS) of the breast, whole-breast irradiation (WBRT) is a standard of care, reducing the absolute rate of in-breast recurrences (IBR) by more than 15% at 10 years, from 28% without radiotherapy to 13 % with radiotherapy. Half of the recurrences occurred as invasive disease. Whereas in the comparative trials, WBRT did not impact on overall survival, survival of patients who recurred with invasive cancers was impaired in comparison to patients who did not recur, or to patients with DCIS-only recurrences.

Using criteria based on age, tumor size, nuclear grade, and margins status, several trials and cohort studies failed to identify subgroups of patients at low risk, who could be safely spared the need for WBRT. The Radiation Therapy Oncology Group (RTOG) DCIS trial included patients treated with BCS for low- or intermediate grade DCIS revealed by unifocal microcalcifications, size ≤25 mm, margins ≥3 mm, and no residual microcalcifications after surgery. The 5-year rates of IBR were 3.5 % without radiotherapy, versus 0.4 % with radiotherapy, and 6.7 % and 0.9 % at 7 years, respectively (p \<0.001). Sixty percent of the patients received tamoxifen in both groups.

Several studies showed that the same molecular classes were identified in DCIS as in invasive cancers. Studies suggested that low proliferation, hormone receptors expression, and lack of ERBB2 amplification were associated with a low risk of IBR in patients not receiving radiotherapy. A combined signature was tested in the Eastern Cooperative Oncology Group (ECOG) trial, showing a 10% IBR rate at ten years in patients with a low-risk.

Identifying very low-risk DCIS, using biological markers in addition to the clinical and histological markers of low-risk DCIS, could help to select patients who could be safely avoided WBRT following BCS. It would avoid over-treatment in these women and could decrease the cost of management.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-03-14
• Study First Submitted QC: 2019-03-14
• Study First Posted: 2019-03-18
• Study Start: 2019-05-10
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-25
• Last Update Posted: 2024-11-27
• Primary Completion: 2029-11-14
• Study Completion: 2034-11-14

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Female
• Target Recruitment: 295

Inclusion Criteria

1. Woman aged ≥50 years,
2. ECOG performance status ≤2
3. Microcalcifications on pre-biopsy mammography, unifocal, ≤25 mm or opacity without microcalcifications and no clinical palpable tumour
4. Absence of suspicious residual microcalcifications either on post-biopsy/ preoperative localization mammography, or on post-operative mammography Note: if absence of residual microcalcifications on post-biopsy/pre-operative mammography, post-operative mammography is not mandatory;
5. Breast-conserving surgical excision;
6. Histologically proven DCIS of the breast without an invasive component; Note Incidental histological finding of DCIS lesions developed within a benign breast lesion as well as an association with classical lobular carcinoma in situ (LCIS) associated with the DCIS are accepted.
7. Free margins (≥2 mm), or free margins following re-excision;
8. Low or Intermediate nuclear grade; Note: In case of nuclear grade heterogeneity within the same sample or between the biopsy or the surgical specimen, the highest nuclear grade score will prevail.
9. Tumour tissue sample availability; Note: Surgical specimen is mandatory unless no residual disease on the surgical specimen. In this instance, the initial diagnosis biopsy is required.
10. Absence of extensive necrosis (≤30% of the lumen diameter);
11. Immunohistochemical characteristics of luminal A subtype: ER≥10 %, PR ≥20 %, HER2 negative (0/1+) or 2+ not amplified (confirmed by fluorescent in situ hybridization (FISH) or chromogenic in situ hybridization (CISH)), Ki67 <15%.
12. Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled visits and examinations and including follow-up;
13. Written informed consent.
14. Affiliation to the French social security.

Exclusion Criteria

1. Endocrine treatment for breast cancer.
2. Previous invasive breast cancer including contralateral breast cancer, either metachronous or synchronous
3. Previous DCIS except contralateral DCIS in complete and continuous remission for more than 5 years
4. Previous other cancers (except basal-cell, carcinoma in situ of the cervix or endometrium), not in complete and continuous remission for more than 10 years
5. Known breast-cancer predisposing germ-cell mutation;
6. Palpable tumour with a diagnosis of DCIS on biopsy
7. Bloody nipple discharge;
8. Histological size >25 mm in one or multiple foci
9. High nuclear grade, including high nuclear grade in heterogeneous tumours;either on biopsy or on surgical specimen
10. Associated microinvasive or invasive component;
11. Presence of tumour cells in lymph nodes detected using H&E or immunohistochemical examination (if lymph node sentinel biopsy or dissection has been performed);
12. Absolute contra-indication to whole-breast irradiation as determined by the referring physician;
13. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study.
14. Pregnant women or breast feeding mothers,

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
No Radiotherapy	No Radiotherapy	No Irradiation- Active surveillance
Radiotherapy	Radiotherapy	two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines

Primary Outcome Measures

Name	Time	Method
5-year cumulative incidence of in-breast cancer recurrences	5 years	Incidence of breast recurrence is determined from the date of last surgery to the date of breast recurrence.

Secondary Outcome Measures

Name	Time	Method
Rate of in-breast recurrences (IBR).	10 years	In-breast recurrence defined as any carcinoma (invasive or in situ) occurring in the treated breast
Long term toxicities	Throughout study completion, up to 10 years.	The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders and so the late effects and sequelea regarding the whole-breast radiotherapy.
Relapse-free survival (RFS)	10 years	RFS is defined as the interval between the date of last surgery and the date of ipsilateral breast recurrence, regional nodes recurrence, distant metastases, of death from breast cancer, whichever occurs first
Quality of life of the patients using EORTC-QLQ-BR23	3 years	Quality of Life of Patients will be assessed using a EORTC-QLQ BR23.It is a 23-item self-reporting specific questionnaire developed to assess the quality of life of breast cancer patients. It permits to evaluate the symptoms of breast cancer and the side effects of treatment.
Cosmetics Evaluation	3 years	cosmetic results will be evaluated by centralized photographic analysis.
Overall survival (OS)	10 years	OS is defined as the interval between the date of last surgery and the date of death from any cause;
Quality of life of the patients using EORTC-QLQ-C 30	3 years	Quality of life will be assessed using QLQ-C 30 questionnaire from the European Organization for Research and Treatment of Cancer (EORTC). It is a 30-item self-reporting questionnaire developed to assess the quality of life of cancer patients. It is grouped into five functional subscales (role, physical, cognitive, emotional and social functioning). In addition, there are three multi-item symptom scales (fatigue, pain, and nausea and vomiting), individual questions concerning common symptoms in cancer patients,and two questions assessing overall Quality of Life
Breast cancer-specific survival (BCSS)	10 years	BCSS is defined as the interval between the date of last surgery and the date of death from breast cancer
Rate of Contralateral breast	10 years	Contralateral breast cancer defined as any carcinoma (invasive or in situ) occurring in the contralateral breast.

Trial Locations

Locations (37)

Institut de Cancérologie de l'Ouest -Site Paul Papin; 🇫🇷 Angers, France

Institut Sainte Catherine; 🇫🇷 Avignon, France

Centre d'Oncologie et de Radiothérapie du Pays Basque; 🇫🇷 Bayonne, France

Clinique Belharra; 🇫🇷 Bayonne, France

Institut Bergonie; 🇫🇷 Bordeaux, France

Centre Francois Baclesse; 🇫🇷 Caen, France

Centre Hospitalier du Cotentin; 🇫🇷 Cherbourg, France

Centre Jean Perrin; 🇫🇷 Clermont-Ferrand, France

CHIC Créteil; 🇫🇷 Créteil, France

Hôpital Henri Mondor; 🇫🇷 Créteil, France

Centre Georges Francois Leclerc; 🇫🇷 Dijon, France

Centre Hospitalier De Lagny Sur Marne; 🇫🇷 Jossigny, France

CHU Saint-Pierre La Réunion; 🇫🇷 La Réunion, France

Centre Guillaume le Conquérant; 🇫🇷 Le Havre, France

Centre Oscar Lambret; 🇫🇷 Lille, France

Chu De Limoges - Hopital Dupuytren; 🇫🇷 Limoges, France

Centre Hospitalier Bretagne Sud; 🇫🇷 Lorient, France

Centre de Radiothérapie Mermoz; 🇫🇷 Lyon, France

Centre Léon Berard; 🇫🇷 Lyon, France

Hôpital La Croix Rousse; 🇫🇷 Lyon, France

Institut Regional Du Cancer Montpellier Val D Aurelle; 🇫🇷 Montpellier, France

Centre Azuréen De Cancérologie; 🇫🇷 Mougins, France

Centre Antoine Lacassagne; 🇫🇷 Nice, France

Centre de Haute Energie; 🇫🇷 Nice, France

Hopital Pitie Salpetriere; 🇫🇷 Paris, France

Institut CURIE; 🇫🇷 Paris, France

Centre Hospitalier Lyon Sud; 🇫🇷 Pierre-Bénite, France

Institut Jean Godinot; 🇫🇷 Reims, France

Centre Eugène Marquis; 🇫🇷 Rennes, France

Centre Frédéric Joliot; 🇫🇷 Rouen, France

Hôpital René Huguenin - Institut Curie; 🇫🇷 Saint-Cloud, France

CHU Saint-Etienne; 🇫🇷 Saint-Étienne, France

Centre De Radiothérapie De La Robertsau; 🇫🇷 Strasbourg, France

Centre Paul Strauss; 🇫🇷 Strasbourg, France

Institut Claudius Regaud; 🇫🇷 Toulouse, France

Institut De Cancerologie De Lorraine Alexis Vautrin; 🇫🇷 Vandœuvre-lès-Nancy, France

Gustave Roussy; 🇫🇷 Villejuif, France